Abstract
Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
CNS & Neurological Disorders - Drug Targets
Title: Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
Volume: 9 Issue: 5
Author(s): Caitlin M. White, Sunggoan Ji, Huan Cai, Stuart Maudsley and Bronwen Martin
Affiliation:
Keywords: Alzheimer's disease, Autism Spectrum Disorders, neurological disorders, Parkinson's disease, pharmacotherapeutics, pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
Abstract: Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G proteincoupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimers disease, Parkinsons disease, and Autism Spectrum Disorders.
Export Options
About this article
Cite this article as:
M. White Caitlin, Ji Sunggoan, Cai Huan, Maudsley Stuart and Martin Bronwen, Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361595
DOI https://dx.doi.org/10.2174/187152710793361595 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Role of Apoptotic Pathways in Alzheimers Disease Neurodegeneration and Cell Death
Current Alzheimer Research Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fluorescence Imaging of Blood Flow Velocity in the Rodent Brain
Current Topics in Medicinal Chemistry A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview
Current Alzheimer Research Phenylbutyric Acid Protects Against Spatial Memory Deficits in a Model of Repeated Electroconvulsive Therapy
Current Neurovascular Research Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets Insights into the Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism
Current Medicinal Chemistry Role of Estrogens on Some Cognition-Related Aspects
Current Topics in Medicinal Chemistry The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology The Importance of Steroidomics in the Study of Neurodegenerative Disease and Ageing
Combinatorial Chemistry & High Throughput Screening Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model
Current Alzheimer Research Decreased Cerebral Perfusion and Oxidative Stress Result in Acute and Delayed Cognitive Impairment
Current Neurovascular Research Nanotubes at Neural and Immune Synapses
Current Medicinal Chemistry 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Multi-Target Compounds Acting in the Central Nervous System Designed From Natural Products
Current Medicinal Chemistry Phosphodiesterase-4 Modulation as a Potential Therapeutic for Cognitive Loss in Pathological and Non-Pathological Aging: Possibilities and Pitfalls
Current Pharmaceutical Design